

**Wrightington, Wigan and
Leigh Teaching Hospitals**
NHS Foundation Trust

Information Governance Department

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2025/11016

Date Received: 18th August 2025

Response Due: 16th September 2025

Date: 29th August 2025

Dear Sir/Madam

With reference to your request for information received on 18th August 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions.

- 1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated?**
83 on SACT (96 including patients on zoledronic acid or epoetin zeta).

If you refer your multiple myeloma patients to another centre, please state which.

Patient would get referred to Manchester Royal Infirmary, The Christie or Salford Royal Foundation Trust for CAR-T or bi-specific initiation for example.

- 2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:**
- Any other systemic anti-cancer therapy = 1.
 - Belantamab Mafodotin [Blenrep] = 0.
 - Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone = 0.
 - Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone = 0.
 - Bortezomib [Velcade] monotherapy or with dexamethasone = 0.
 - Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) = 2.
 - Bortezomib, thalidomide and dexamethasone [VTD] = 0.
 - Carfilzomib [Kyprolis] and dexamethasone = 4.
 - Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone = 0.

- Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone = 12.
- Daratumumab [Darzalex] monotherapy = 4.
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) = 21.
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) = 6.
- Elranatamab = 2.
- Idecabtagene vicleucel [Abecma] = 0.
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) = 0.
- Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) = 7.
- Lenalidomide [Revlimid] and dexamethasone = 9.
- Lenalidomide [Revlimid] monotherapy = 16.
- Panobinostat in combination with Bortezomib and Dexamethasone = 0.
- Pomalidomide [Imnovid] and dexamethasone = 2.
- Selinexor and dexamethasone = 0.
- Selinexor, Bortezomib [Velcade] and dexamethasone = 1.
- Talquetamab = 0.
- Teclistamab [Tecvayli] = 0.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111